



Publicaciones en revistas indexadas en inglés

1. Treatment of autoimmune hemolytic anemia: real-world evidence from a reference center in Mexico. Jaime-Pérez JC, et al. (Autor 4/5) *Blood Res* 2019;54:131-136 doi: 10.5045/br.2019,54.2.131
 2. Treatment of classical Hodgkin's lymphoma in children and adolescents. Gómez-Almaguer D, et al. (Autor 4/4) *Expert Opin Pharmacother* 2019;20:1227-1234 doi:10.1080/14656566.2019.1606212
 3. Determine safety of outpatient chemotherapy and autotransplants using refrigerated, non-frozen grafts in persons with multiple sclerosis. Gale RP, et al. (Autor 6/12) *Clin Transplant* 2019;33:e13567 doi: 10.1111/ctcr.13567
 4. Efficacy of three filgrastim-intended copies for hematopoietic stem cell mobilization in healthy adult and pediatric donors in Mexico. Gómez-De León A, et al. (Autor 1/13). *J Clin Apher* 2019 doi 10.1002/jca.21707
 5. Clinical presentation in thrombotic thrombocytopenic purpura: Real-world data from two Mexican institutions. Bugarin-Estrada, et al. (Autor 2/9) *J. Clin Apher* 2018 (Aceptado para publicación)
 6. Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico. Tarín-Arzaga, et al. (Autor 6/10) *Cancer* 2018; Feb 20. Doi 10.1002/cncr.31305
 7. Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia. *Br J Haematol* 2017 Dec 21. Doi 10.1111/bjh.15070
 8. Danazol as first-line therapy for myelodysplastic syndrome. Colunga-Pedraza PR, et al. (Autor 10/12) *Clin Lymphoma Myeloma Leuk* 2018;18:e109-e113, Doi 10.1016/j.clml.2017.11.007
 9. Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective. Gómez-de-León A, et al. (Author 1/4) *Expert Rev Hematol* 2017;10:809-19. DOI: 10.1080/17474086.2017.1360180. PMID: 28742419
 10. Age acts as an independent variable for survival in acute lymphoblastic leukemia: data from a cohort in Northeast Mexico. Jaime-Pérez JC, et al. (Author 4/7) *Clin Lymphoma Myeloma Leuk* 2017;17:590-4. DOI: 10.1016/j.clml.2017.06.016. PMID: 28689002
 11. Measurements of catheter, venous, and capillary cyclosporine A blood are comparable and useful in pediatric hematopoietic stem cell transplant recipients. González-Llano O, et al. (Author 4/11) *Acta Haematologica* 2017;137:113-16. DOI: 10.1159/000455817. PMID: 28226327
 12. TNF- α increases in CSF of children with acute lymphoblastic leukemia before CNS relapse. Jaime-Pérez JC, et al. (Author 6/7). *Blood Cells Molecules and Diseases* 2017;63:27-31. DOI 10.106/j.bcmd.2016.12.011. PMID: 28061377
 13. Intrathecal delivery of bone marrow stem cells in ALS: A preliminary report. Martínez HR, et al. (Author 7/9). *Transplant Open* 2017;2:1-6. DOI: 10.15761/JTO.1000117
 14. Acute Leukemia characteristics are different around the world: the Mexican perspective. Gómez-Almaguer D, et al. (Author 14/15). *Clinical Lymphoma Myeloma and Leukemia* 2017;17:46-51. DOI: 10.1016/j.clml.2016.09.003. PMID: 27742477
-



15. Comparative analysis of iron status and other hematological parameters in preeclampsia. Gutiérrez-Aguirre CH, et al. (Author 7/12). Hematology 2017;22(1):36-40. DOI: 10.1080/10245332.2016.1220120. PMID: 27558940
 16. More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura. Vázquez-Mellado A, et al. (Author 6/11) Hematology 2016;21:311-6 DOI 10.1080/10245332.2015.1133008. PMID: 26907228
 17. Clearance of donor cell leukemia by means of graft versus leukemia effect. A case report. Ruiz-Delgado GJ, et al. (Author 3/4) Hematology 2015;22:36-40. DOI 10.1080/10245332.2015.1117741. PMID: 26914843.
 18. No clinically relevant differences between capillary and venous blood cell counts in adult haematological patients using a nonautomated lancet. Herrera-Rojas MA, et al. (Author 3/10) International Journal of Laboratory Hematology 2015;37:e115-8. DOI: 10.1111/ijlh.12340. PMID: 25801733
 19. Effective collection of peripheral blood stem cells in children weighing 20 kilograms or less in a single large-volume apheresis procedure. Salazar-Riojas R, et al. Journal of Clinical Apheresis 2015; 30:281-7. DOI 10.1002/jca.21375. PMID: 25557252
 20. Is there still a role for low-dose all-transretinoic acid in the treatment of acute promyelocytic leukemia in the arsenic trioxide era? Jaime-Pérez JC, et al. (Author 4/7) Clinical Lymphoma Myeloma and Leukemia 2015;15:816-19. DOI 10.1016/j.clml.2015.09.002. PMID: 26500134
 21. Health-related quality of life in leukemia survivors of allogeneic hematopoietic stem cell transplantation employing the Mexican reduced-intensity conditioning. González-Ramírez MP et al. (Autor 3/13) Revista de Investigación Clínica 2015;67:109-16 PMID: 26500134
 22. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Gómez-Almaguer D, et al. (Author 4/9) Blood 2014;123(25):3906-3908. DOI: 10.1182/blood-2014-01-549360, PMID: 24802773
 23. Safety and tolerability of intrathecal delivery of autologous bone marrow nucleated cells in children with cerebral palsy: an open-label phase I trial. Mancías-Guerra, et al. (Autor 13/16) Cytotherapy 2014;16:810-20. DOI: 10.1016/j.jcyt.2014.01.008, PMID: 24642016
 24. Allogeneic peripheral blood stem cell transplantation using reduced-intensity conditioning in an outpatient setting in ABO-incompatible patients: are survival and graft-versus-host disease different? Gutiérrez-Aguirre CH et al. (Autor 2/9) Transfusion 2014;54:1269-1277. DOI: 10.1111/trf.12466, PMID: 24898453
 25. Current approaches for the treatment of autoimmune hemolytic anemia. Jaime-Pérez JC et al. (Autor 3/5) Archivum immunologiae et therapiae experimentalis 2013;61:385-95. DOI: 10.1007/s00005-013-0232-3, PMID: 23689532
 26. Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: report of four cases. Pequeño-Luévano M et al. (Autor 4/7) Hematology 2013;18:233-6. DOI: 10.1179/1607845412Y.0000000073, PMID: 23432850
-



Publicaciones en revistas indexadas en español

1. Hematología pública y privada: diferencias y similitudes entre pacientes de consulta de primera vez. Solano-Herrejón KY, et al. (Autor 2/6) Rev Hematol Mex 2018;19:115-122
2. A propósito de un adulto joven con leucemia linfoblástica en tercera recaída: no todo está perdido. Márquez-Pinedo O, et al. (Author 2/4) Rev Hematol Mex 2017;18:127-133.
3. ¿Es de utilidad realizar una PET-CT intermedia para guiar el tratamiento inicial de pacientes con linfoma de Hodgkin? Costo-beneficio en el mundo real. Gómez-De León A (Author 1/8) Rev Hematol Mex 2017;18: 6-15
4. Algunas observaciones sobre la historia del linfoma de Hodgkin. Gómez-De León A (Author 1/1) Rev Hematol Mex 2010;11: 208-212

Publicaciones no arbitradas

1. Neoplasias mieloproliferativas crónicas. Capítulo 14 (Autor 2/2) Fundamentos de la Hematología. Editorial Médica Panamericana 5ª Ed 2014;195-203. Ciudad de México, México. ISBN 9786077743040
2. Anemia megaloblástica. Capítulo 7 (Autor 2/2) Hematología La sangre y sus enfermedades. McGraw-Hill 4ª Ed 2015;28-30. Ciudad de México, Mexico. ISBN 9786071512918
3. Anemia hemolítica autoinmune. Capítulo 13 (Autor 2/2) Hematología La sangre y sus enfermedades. McGraw-Hill 4ª Ed 2015;28-30. Ciudad de México, México. ISBN 9786071512918

Presentaciones en congresos internacionales

1. Assessing patients' knowledge and attitudes towards HSCT in an outpatient-based transplant center in Mexico. Bugarin-Estrada E, et al. (Autor 2/5). 2019 Transplantation and Cellular Therapy Meetings, Houston Texas Febrero 2019. Presentación en poster.
 2. Do outcomes differ according to patients' socioeconomic status? Real-world data from an outpatient-based center in Mexico. Bugarin-Estrada E, et al. (Autor 3/6) 2019 Transplantation and Cellular Therapy Meetings, Houston Texas Febrero 2019. Presentación en poster.
 3. HLA-matched related versus haploidentical peripheral blood stem cell transplantation in adults and children. Real world outcomes in Mexico. Gómez-De León A, et al. Autor 3/6) 2019 Transplantation and Cellular Therapy Meetings, Houston Texas Febrero 2019. Presentación en poster.
 4. Donor lymphocyte infusion from G-CSF-primed, unmanipulated whole blood is safe and improves chimerism in HLA-matched and haploidentical transplantation. Gómez-De León A, et al. (Autor 1/8) American Society of Hematology 60th Annual Meeting and Exposition, San Diego CA, Diciembre 2018. Presentación en poster.
-



5. Cytokine release syndrome after peripheral blood T-cell replete haploidentical transplantation is not prevented by dexamethasone and limits its full outpatient conduction. Colunga-Pedraza P, et al. (Autor 2/10). American Society of Hematology 60th Annual Meeting and Exposition, San Diego CA, Diciembre 2018. Presentación en poster.
 6. Newly diagnosed pernicious anemia can be treated with a single dose of cobalamin. Results of a pilot trial. Pezina-Cantú CO (Autor 3/10). American Society of Hematology 60th Annual Meeting and Exposition, San Diego CA, Diciembre 2018. Presentación en poster.
 7. Supplementation with selenium as prevention for the development of mucositis in patients undergoing HSCT. Results of a pilot study. Cantú-Rodríguez OG, et al. (Autor 6/9) American Society of Hematology 60th Annual Meeting and Exposition, San Diego CA, Diciembre 2018. Presentación en poster.
 8. Outpatient autotransplants for persons with multiple sclerosis. Gómez-Cruz G, et al. (Autor 6/12). American Society of Hematology 60th Annual Meeting and Exposition, San Diego CA, Diciembre 2018. Presentación en poster.
 9. Outpatient clinic visits as a measure of disease burden: Insights from a university hospital in Mexico. Septiembre 16, 2018. 37th World Congress of the International Society of Hematology, Vancouver, Canada. Health Resources and Outcomes Research Session. Presentación oral.
 10. Metformin plus R-CHOP in patients with diffuse large B-cell lymphoma. Preliminary results of a phase I/II study. Non-Hodgkin Lymphoma Session. Septiembre 15, 2018. 37th World Congress of the International Society of Hematology, Vancouver Canada.
 11. Hemorrhagic cystitis in haploidentical transplant recipients after outpatient conditioning: a single center experience. 37th World Congress of the International Society of Hematology, Vancouver Canada, September 2018. Presentación en poster.
 12. Low-dose plerixafor is effective and less costly for peripheral blood stem cell mobilization in patients with lymphoma and multiple myeloma undergoing autologous transplantation. Gómez-Almaguer D, et al (Autor 4/9) Biology of Blood and Marrow Transplantation 2018;24:S141. Bone marrow transplantation tandem meetings Salt Lake City, UT Febrero 2018
 13. Modifications to the "classical" autologous hematopoietic stem cell transplantation in multiple sclerosis: efficacy and safety study of a less toxic approach which improves the neurological condition: a Mexican perspective. Ruiz-Arguelles JG, et al (Autor 8/9) Biology of Blood and Marrow Transplantation 2018;24:S141. Bone marrow transplantation tandem meetings Salt Lake City, UT Febrero 2018
 14. Outpatient haploidentical stem cell transplantation using post-transplant cyclophosphamide is feasible. Experience in a single Latin-american center. Colunga-Pedraza PR, et al. (Author 2/12) American Society of Hematology 59th Annual Meeting and Exposition, Atlanta GA, Dic 2017
 15. Low dose rituximab is a useful addition to corticosteroids for newly diagnosed patients with warm autoimmune hemolytic anemia. Gómez-De León A, et al. (Autor 1/9) May 18, 2017; 181191. European Hematology Association, Madrid, España Junio 2017 (E-poster)
 16. Impact of the affordability of novel agents in patients with multiple myeloma: real world data on current clinical practice in Mexico. Tarín-Arzaga L, et al. May 18, 2017; 181082 European Hematology Association, Madrid España Junio 2017 (E-poster)
-



17. Filgrastim biosimilars for peripheral blood hematopoietic stem cell mobilization in healthy donors: a five-year experience from a university hospital in Mexico. Gómez-Almaguer D, et al. (Autor 2/8). *Biology of Blood and Marrow Transplantation* 2017;23:S272-273. Bone marrow transplantation Tandem Meetings, Orlando, FL Febrero 2017
18. Outpatient-based haploidentical peripheral blood stem cell transplantation (HSCT) with post-transplantation cyclophosphamide in refractory/relapsed hematological malignancies. Single center experience in Mexico. Gómez-Almaguer D, et al. (Autor 4/9). *Biology of Blood and Marrow Transplantation* 2017;23:S272. Bone marrow transplantation Tandem Meetings, Orlando, FL Febrero 2017
19. Eltrombopag, low-dose rituximab and high-dose dexamethasone combination for patients with newly diagnosed immune thrombocytopenia: a pilot "total therapy" study. Gómez-Almaguer D, et al. (Autor 10/12) Abstract 1369. American Society of Hematology 58th Annual Meeting and Exposition, San Diego, CA Diciembre 2016
20. Low dose rituximab and plasma exchange as frontline therapy for patients with thrombotic thrombocytopenic purpura. Vázquez-Mellado A, et al. (Author 6/10). *Blood* 2015; 126:2257. American Society of Hematology 57th Annual Meeting and Exposition, Orlando, FL Diciembre 2015
21. Health-related quality of life in survivors of allogeneic hematopoietic stem cell transplantation employing the Mexican reduced-intensity conditioning. Labastida-Mercado N, et al. (Autor 5/14). *Biology of blood and marrow transplantation* 2015;21(2) S179. Bone marrow transplantation tandem meetings San Diego, CA Febrero 2015
22. Eltrombopag and high-dose dexamethasone as first line treatment for ITP. Gómez-Almaguer D, et al. (Autor 3/9). American Society of Hematology 56th Annual Meeting and Exposition, New Orleans, LA Diciembre 2013

Participaciones en congresos Internacionales y reuniones no arbitradas

- Status of HSCT in Latinamerica session (Mexico). Presentación oral. 6th WBMT/WHO Workshop. Worldwide Network for Blood and Marrow Transplantation, Asunción Paraguay, Septiembre 2, 2019
 - How to handle ABO incompatibilities (Graft and platelet transfusions). Panel de discusión. 6th WBMT/WHO Workshop. Worldwide Network for Blood and Marrow Transplantation, Asunción Paraguay, Septiembre 3, 2019
 - Controlled vs. uncontrolled vs. no cryopreservation of stem cell grafts. Panel de discusión. 6th WBMT/WHO Workshop. Worldwide Network for Blood and Marrow Transplantation, Asunción Paraguay, Septiembre 3, 2019
-